Tag: Cheuvreux
SAF-HOLLAND: Kepler Cheuvreux is not inspired by the dossier
Kepler Cheuvreux’s research has confirmed his opinion on the title and remains neutral. The target price continues to be at EUR 12. Zonebourse with dpa-AFX Analyzer 2022 All the news…
STABILUS: Kepler Cheuvreux maintains its negative opinion
Kepler Cheuvreux retains his opinion and remains to sell. The target price is not modified at 53 EUR. Zonebourse with dpa-AFX Analyzer 2022 All the news about STABILUS SA 16:29…
Acticor Biotech announces coverage of its title by Gilbert Dupont and Kepler Cheuvreux – 12/01/2022 at 6:00 p.m.
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected] ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specializing in…
BNP PARIBAS: Kepler Cheuvreux raises his opinion
Initially neutral, broker Kepler Cheuvreux via its analyst Jacques-Henri Gaulard adopts a positive opinion and recommends the stock to be bought. The price target is increased to 65.30 EUR against…
HORNBACH HOLDING: Kepler Cheuvreux for purchase
In a research note published by Ludovic Allegre, broker Kepler Cheuvreux advises to approach the stock with a purchase opinion. The price target remains unchanged 130 EUR. Zonebourse with dpa-AFX…
AMS: Kepler Cheuvreux still for purchase
Kepler Cheuvreux is positive and recommends the title to be purchased. The target price is always fixed at 22 CHF. Zonebourse with dpa-AFX Analyzer 2021 All news on AMS AG…
SHOP APOTHEKE EUROPE NV: Kepler Cheuvreux retains its negative opinion
Analyst Olivier Calvet of Kepler Cheuvreux remains the sale on the record. The price target continues to be 89 EUR. Zonebourse with dpa-AFX Analyzer 2021 All the news on SHOP…